This overview of the fifth edition of the WHO classification of thymic epithelial tumors
(including thymomas, thymic carcinomas, and thymic neuroendocrine tumors [NETs]) …

Small-cell lung cancer (SCLC), an aggressive neuroendocrine tumor with early
dissemination and dismal prognosis, accounts for 15–20% of lung cancer cases and∼ …

Introduction: Epithelial circulating tumor cells (CTCs) are detectable in patients with non-
small cell lung cancer (NSCLC). However, epithelial to mesenchymal transition, a widely …

Purpose Recent advances in treatment of lung cancer require greater accuracy in the
subclassification of non–small-cell lung cancer (NSCLC). Targeted therapies which inhibit …

The global physiological effects of glucocorticoids are well established, and the framework
of transcriptional regulation by the glucocorticoid receptor (GR) has been described …

S100 protein is a sensitive marker for melanomas and peripheral nerve sheath tumors. It is,
however, expressed by other mesenchymal and epithelial tumors. Despite its low specificity …

Purpose: The monocarboxylate transporter 1 (MCT1) inhibitor, AZD3965, is undergoing
phase I evaluation in the United Kingdom. AZD3965 is proposed, via lactate transport …

Introduction: The 2004 version of the World Health Organization classification subdivides
thymic epithelial tumors into A, AB, B1, B2, and B3 (and rare other) thymomas and thymic …

The importance of intratumour genetic and functional heterogeneity is increasingly
recognised as a driver of cancer progression and survival outcome. Understanding how …

The ovary is a common site of involvement for metastasis and the breast is one of the most
common sources. Metastatic breast carcinoma can mimic a primary ovarian carcinoma …